EUVIMEDEUVIMED entdecken
Crossref

CD133 ligand‐enhanced etoposide‐liposome complex for targeted killing of lung cancer cells

Shiwei Nie, Junzheng Zhou, Xiaodong Zheng, Xudong Wei, Jinrui Zhang, Xiaojuan Shen, Weimin Zhang iD

Biotechnology Progress · 2024

DOI: 10.1002/btpr.3460 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biotechnology Progress, 2024. Verfasst von Shiwei Nie und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Anyang Tumor Hospital, The Affiliated Anyang Tumor Hospital of Henan University of Science and Technology, Anyang Cit…. Hauptthemen laut MEDLINE: Etoposide, Lung Neoplasms, Liposomes, AC133 Antigen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lung cancer has a high incidence rate and a low cure rate, hence the urgent need for effective treatment methods. Current lung cancer drugs have several drawbacks, including low specificity, poor targeting, drug resistance, and irreversible damage to normal tissues. Therefore, there is a need to develop a safe and effective new drug that can target and kill tumor cells. In this study, we combined nanotechnology and biotechnology to develop a CD133 ligand‐modified etoposide‐liposome complex (Lipo@ETP‐CD133) for targeted therapy of lung cancer. The CD133 ligand targeted lung cancer stem cells, causing the composite material to aggregate at the tumor site, where high levels of ETP liposomes could exert a strong tumor‐killing effect. Our research results demonstrated that this nano‐drug had efficient targeting and tumor‐killing effects, indicating its potential for clinical application.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EtoposideLung NeoplasmsLiposomesAC133 AntigenHumansCell Line, TumorAnimalsLigandsMiceDrug Delivery SystemsNeoplastic Stem Cells

Stichwörter der Autor:innen

CD133 ligandLipo@ETPliposomelung cancernanomaterial

Substanzen

EtoposideLiposomesAC133 AntigenLigandsPROM1 protein, human

Autor:innen und Institutionen

  • Department of Thoracic Surgery, Anyang Tumor Hospital, The Affiliated Anyang Tumor Hospital of Henan University of Science and Technology, Anyang City, Henan Province, China.
  • Supply House, Anyang Tumor Hospital, The Affiliated Anyang Tumor Hospital of Henan University of Science and Technology, Anyang City, Henan Province, China.

ORCID-Profile: Weimin Zhang

Zitieren

APA

Nie, S., Zhou, J., Zheng, X., Wei, X., Zhang, J., Shen, X., & Zhang, W. (2024). CD133 ligand‐enhanced etoposide‐liposome complex for targeted killing of lung cancer cells. Biotechnology Progress. https://doi.org/10.1002/btpr.3460

Vancouver

Nie S, Zhou J, Zheng X, Wei X, Zhang J, Shen X, et al. CD133 ligand‐enhanced etoposide‐liposome complex for targeted killing of lung cancer cells. Biotechnology Progress. 2024. doi:10.1002/btpr.3460

BibTeX
@article{Nie2024,
  author = {Nie, Shiwei and Zhou, Junzheng and Zheng, Xiaodong and Wei, Xudong and Zhang, Jinrui and Shen, Xiaojuan and Zhang, Weimin},
  title = {CD133 ligand‐enhanced etoposide‐liposome complex for targeted killing of lung cancer cells},
  journal = {Biotechnology Progress},
  year = {2024},
  doi = {10.1002/btpr.3460}
}
Kostenlos starten →